Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.22, no.3, pp.533-536, 2016 (SCI-Expanded)
- Publication Type: Article / Article
- Volume: 22 Issue: 3
- Publication Date: 2016
- Doi Number: 10.1177/1078155215572930
- Journal Name: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.533-536
- Keywords: Melanoma, ipilimumab, cytotoxic T-lymphocyte antigen-4, radiotherapy, dermatitis, RADIATION-THERAPY, LOCAL RADIATION, HIGH-RISK, ADJUVANT RADIOTHERAPY, MELANOMA, INHIBITION, LYMPHADENECTOMY, IMMUNOTHERAPY, ANTIBODY, PATIENT
- Akdeniz University Affiliated: Yes
Abstract
Ipilimumab, monoclonal antibody against cytotoxic T-lymphocyte antigen-4 and, radiotherapy are commonly used to treat unresectable and metastatic melanoma. As a result of upregulation of immune system with ipilimumab, many immune-related adverse effects, such as dermatitis, colitis, hepatitis, and hypophysitis, have been previously reported in literature. Typically, these effects are treated with high-dose steroids and mostly heal up. Here, we report a case who was receiving radiotherapy due to metastatic malignant melanoma with atypical generalized rash, which was enlarged with concurrent ipilimumab treatment.